Name: Heidi B. Ramstad
Title: Chief Medical Officer
Born: 1969
Holdings: –
Education: Pediatrician, Ph.D. in Medicine from the Norwegian University of Science and Technology (NTNU), Trondheim.
Previous experience: Heidi B. Ramstad has more than 25 years’ experience as a physician and manager within big pharma, med-tech and startups. Her most recent positions include Chief Medical Officer at Nisonic AS, AlgiPharma AS and Immedica AB. In addition, she has worked with several major pharmaceutical companies, such as Roche and GSK, serving as Country Medical Director for Norway, and at Pfizer as the Nordic Medical Director for Specialty Care.
Other assignments: Advisor, The Research Council of Norway.
Name: Erik Kinnman
Title: CEO
Born: 1958
Holdings: 3,685,578 employee stock options 2023/2026
Education: MD, Board certified Neurologist, Ph.D., Assoc. Prof. at Karolinska Institutet, and Executive MBA from the Stockholm School of Economics.
Previous experience:Erik Kinnman has more than 27 years of experience from senior positions within Life Science, most recently from a position as CEO of Sprint Bioscience. He has previously been the CEO of Abliva AB and has held senior positions at AstraZeneca and SOBI, among others, and worked as a financial analyst at Danske Bank.
Other assignments: Board member of Stayble Therapeutics and Immune System Regulation.
Name: Robert Maiorana
Title: Acting Chief Financial Officer
Born: 1960
Holdings: 20,000 shares and 1,264,946 employee stock options 2023/2026
Education: Bachelor of Science in Business and Economics from Lund University
Previous experience: Robert Maiorana has worked for Vivesto since the second half of 2020 and as Finance Manager since March 2021. Robert has extensive finance experience from senior positions. He has previously worked as a Finance and Management Consultant at Nacka Municipality and Bactiguard Holding AB and CFO at International Copyright Enterprise Services AB, ParaCell Solutions AB and MFEX Mutual Funds Exchange AB. He was also Head of Finance at Ryds Bilglas AB and ABN AMRO Bank Sweden.
Name: Nina Herne
Title: Chief Development Officer
Born: 1969
Holdings: –
Education: PhD in Immunology from Lund University and Executive MBA from Stockholm School of Economics.
Previous experience: Nina Herne has over 20 years of experience from leading positions in pharmaceutical and biotech companies. She has been CEO of Zymenex and LIDDS and was responsible for research and development of biotech products at Chiesi. Nina Herne is engaged as a consultant by Vivesto.
Other assignments: –
Name: Johanna Röstin
Title: Chief Regulatory Officer
Born: 1967
Holdings: 895,193 employee stock options 2023/2026
Education: M.Sc in chemical engineering / biotechnology and a Licentiate degree in biotechnology from the KTH Royal Institute of Technology in Stockholm
Previous experience: Johanna Röstin has more than 25 years of experience within the Pharmaceutical and Biotech industry with expertise within development, project management and regulatory affairs. She was previously Director of CMC, Program Management and Regulatory at OxThera AB and before that she spent 10 years at Swedish Orphan Biovitrum AB (Sobi), where she was regulatory responsible for one of Sobi’s leading biological products commercialized in the EU and US as Global Senior Regulatory Affairs Manager. She was also Regulatory CMC expert for commercial- and development-stage biological products at SOBI. Other employers include Pharmacia and Biovitrum.
Name: Kai Wilkinson
Title: Chief Technical Officer
Born: 1981
Holdings: 661,664 employee stock options 2023/2026
Education: PhD In Inorganic chemistry from was previously University of Agricultural Sciences, MSc. In Chemical Engineering and Biotechnology from Mälardalen University.
Previous experience: Kai Wilkinson was previously Head of Research, Development and Manufacturing at Oasmia. Before joining Oasmia in 2021 he spent 8 years in different positions at Fresenius Kabi AB, including Formulation Scientist and CMC Lead, Parenteral emulsions product specialist, and Pilot Plant production process development.
